A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

Cannot have received: systemic anti-lymphoma therapy

Exception: prednisone/equivalent up to 100 mg daily x 7 days is permissible; localized radiation, steroids and antibiotics are permitted

No prior systemic anti-lymphoma therapy (prednisone/equivalent up to 100 mg daily x 7 days is permissible); localized radiation, steroids and antibiotics are permitted

Cannot have received: solid organ transplantation

Prior solid organ transplantation

Cannot have received: allogeneic stem cell transplantation

Prior allogeneic stem cell transplantation

Cannot have received: systemic immunotherapeutic agents

Prior treatment with systemic immunotherapeutic agents, including but not limited to, radio-immuno-conjugates, antibody-drug conjugates, immune/cytokines and monoclonal antibodies (mAbs) (e.g., anti-cytotoxic T lymphocyte associated protein 4, anti-PD-1, and anti-PD-L1) within 4 weeks or five half-lives of the drug, whichever is shorter

Cannot have received: monoclonal antibody

Prior use of any monoclonal antibody for the purposes of treating cancer within 3 months of the start of Cycle 1

Cannot have received: investigational therapy

Any investigational therapy for the purposes of treating cancer within 28 days prior to the start of Cycle 1

Cannot have received: radiotherapy to the mediastinal/pericardial region

Exception: Radiotherapy to non-target lesion sites will be permitted.

Prior radiotherapy to the mediastinal/pericardial region